CRANBURY, N.J.--(BUSINESS WIRE)--CURE Media Group’s flagship product, CURE® magazine, the nation’s leading consumer digital and print media enterprise focusing on patients with cancer, will be hosting its monthly TweetChat on Wednesday, June 27, at 1 p.m. EDT, for readers to ask questions and to facilitate discussions about the recent specialty issue on immunotherapy.
“We’re looking forward to the next edition of #CureConnect TweetChat that will discuss patients’ stories and experiences with immunotherapy. We hope you can all join us,” said Michael J. Hennessy Jr, president of MJH Associates, parent company of CURE®.
CURE® welcomes all patients and their loved ones, as well as health care professionals, advocates and nonprofit organizations to join the chat by using the hashtag #CureConnect. The below highlights from the special issue will lead the discussion:
The Jury Is Out: Checkpoint inhibitors can be extremely effective for the right patients, but identifying who will benefit remains an imprecise science;
Under New Management: a new expert guideline for managing the side effects of checkpoint inhibitors has been released;
Contagious Enthusiasm: Oncolytic, or engineered, viruses are emerging as promising delivery systems for cancer-killing drugs;